MCID: SCH012
MIFTS: 51

Schizoaffective Disorder

Categories: Mental diseases

Aliases & Classifications for Schizoaffective Disorder

MalaCards integrated aliases for Schizoaffective Disorder:

Name: Schizoaffective Disorder 12 72 51 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5418
ICD10 32 F25 F25.9
ICD9CM 34 295.7
MeSH 41 D011618
NCIt 46 C94378
UMLS 69 C0036337

Summaries for Schizoaffective Disorder

Disease Ontology : 12 A psychotic disorder that is characterized by recurring episodes of mood fluctuations and a loss of contact with reality.

MalaCards based summary : Schizoaffective Disorder is related to schizophreniform disorder and hyperprolinemia. An important gene associated with Schizoaffective Disorder is DISC1 (Disrupted In Schizophrenia 1), and among its related pathways/superpathways are Neuroscience and Monoamine GPCRs. The drugs Dopamine and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Schizoaffective disorder (SZA, SZD or SAD) is a mental disorder characterized by abnormal thought... more...

Related Diseases for Schizoaffective Disorder

Diseases related to Schizoaffective Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 schizophreniform disorder 30.5 COMT DRD2 PRL
2 hyperprolinemia 30.2 COMT PRODH
3 delusional disorder 30.1 DRD2 DRD3
4 tardive dyskinesia 30.0 COMT DRD2 DRD3 HTR2A
5 anxiety 29.9 BDNF COMT HTR2A SLC6A4
6 cocaine dependence 29.9 DRD2 DRD3 SLC6A4
7 paranoid schizophrenia 29.7 BDNF COMT HTR2A SLC6A4
8 schizotypal personality disorder 29.7 COMT SULT4A1
9 pathological gambling 29.6 DRD2 DRD3 HTR2A SLC6A4
10 bipolar i disorder 29.6 BDNF COMT DTNBP1 HTR2A SLC6A4
11 borderline personality disorder 29.5 BDNF COMT HTR2A SLC6A4
12 mood disorder 29.3 BDNF COMT DAOA DISC1 DRD2 HTR2A
13 personality disorder 29.2 BDNF COMT DRD2 DRD3 HTR2A SLC6A4
14 substance abuse 29.0 BDNF COMT DRD2 DRD3 PRL SLC6A4
15 early-onset schizophrenia 29.0 BDNF COMT DRD2 DRD3 HTR2A SLC6A4
16 obsessive-compulsive disorder 28.8 BDNF COMT DRD2 DRD3 HTR2A PRL
17 bipolar disorder 28.5 BDNF COMT DAOA DISC1 DRD2 DRD3
18 major depressive disorder 28.5 BDNF COMT DISC1 DRD2 DRD3 HTR2A
19 alcohol dependence 28.4 BDNF COMT DRD2 DRD3 GABRB1 HTR2A
20 schizophrenia 27.2 BDNF CHRFAM7A COMT DAOA DISC1 DRD2
21 psychotic disorder 27.0 BDNF COMT DAOA DISC1 DRD2 DRD3
22 schizophrenia 4 10.8
23 schizophrenia 2 10.8
24 schizophrenia 9 10.8
25 schizophrenia 15 10.8
26 chromosome 2p16.3 deletion syndrome 10.8
27 schizophrenia 18 10.8
28 schizophrenia 19 10.8
29 galactorrhea 10.4 DRD2 PRL
30 obsessive-compulsive personality disorder 10.4 DRD3 SLC6A4
31 alzheimer disease 5 10.3 HTR2A SLC6A4
32 alcohol use disorder 10.3 DRD2 SLC6A4
33 prolactin producing pituitary tumor 10.3 DRD2 PRL
34 polysubstance abuse 10.3 COMT DRD2 DRD3
35 impulse control disorder 10.3 DRD2 DRD3
36 alcohol-induced mental disorder 10.3 DRD2 SLC6A4
37 social phobia 10.2 DRD2 PRL SLC6A4
38 opiate dependence 10.2 DRD2 DRD3 SLC6A4
39 mammographic density 10.2 COMT PRL
40 oppositional defiant disorder 10.2 COMT DRD2 SLC6A4
41 alexithymia 10.2 COMT DRD2 SLC6A4
42 restless legs syndrome 10.2 COMT DRD2 DRD3
43 psychosexual disorder 10.2 HTR2A SLC6A4
44 childhood-onset schizophrenia 10.2 COMT DAOA PRL PRODH
45 cocaine abuse 10.2 DRD2 PRL SLC6A4
46 antisocial personality disorder 10.2 COMT DRD2 SLC6A4
47 traumatic brain injury 10.2 BDNF COMT DRD2
48 alcoholic psychosis 10.2 DRD2 HTR2A SLC6A4
49 conduct disorder 10.2 COMT DRD2 SLC6A4
50 periodic limb movement disorder 10.2 DRD2 HTR2A SLC6A4

Graphical network of the top 20 diseases related to Schizoaffective Disorder:



Diseases related to Schizoaffective Disorder

Symptoms & Phenotypes for Schizoaffective Disorder

MGI Mouse Phenotypes related to Schizoaffective Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 BDNF COMT DISC1 DRD2 DRD3 DTNBP1
2 homeostasis/metabolism MP:0005376 9.73 PRL PRODH SLC1A1 SLC6A4 BDNF COMT
3 nervous system MP:0003631 9.44 DRD3 DTNBP1 GABRB1 NOTCH4 PRL PRODH

Drugs & Therapeutics for Schizoaffective Disorder

Drugs for Schizoaffective Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 378)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
3
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
4
Donepezil Approved Phase 4 120014-06-4 3152
5
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
6
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
7
Clozapine Approved Phase 4,Phase 1 5786-21-0 2818
8
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Ziprasidone Approved Phase 4,Phase 2,Phase 3 146939-27-7 60854
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1 10118-90-8 5281021
13
Pimozide Approved Phase 4 2062-78-4 16362
14
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
15
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
16
Perphenazine Approved Phase 4 58-39-9 4748
17
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
18
Fluphenazine Approved Phase 4 69-23-8 3372
19 Benperidol Approved, Investigational Phase 4 2062-84-2
20 bromperidol Approved, Investigational Phase 4 10457-90-6
21
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 1 68693-11-8 4236
22
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 1 112111-43-0
23 Perazine Approved, Investigational Phase 4 84-97-9
24
Ethanol Approved Phase 4,Phase 1,Phase 2 64-17-5 702
25
Norepinephrine Approved Phase 4 51-41-2 439260
26
Cocaine Approved, Illicit Phase 4,Phase 3 50-36-2 446220 5760
27
Nicotine Approved Phase 4,Phase 2,Phase 3 54-11-5 89594 942
28
Pravastatin Approved Phase 4 81093-37-0 54687
29
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
30
Metformin Approved Phase 4,Phase 3 657-24-9 4091 14219
31
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1 99-66-1 3121
32
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
33
Galantamine Approved Phase 4,Phase 3,Phase 2 357-70-0 9651
34
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
35
Allopurinol Approved Phase 4 315-30-0 2094
36
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
37
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 3007 5826
38
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
39
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
40
Pramlintide Approved, Investigational Phase 4 151126-32-8
41
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
42
Amantadine Approved Phase 4,Phase 3,Phase 1 768-94-5 2130
43
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
44
Lorazepam Approved Phase 4,Phase 3,Phase 2 846-49-1 3958
45
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2 249296-44-4 5310966
46
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
47
Asenapine Approved Phase 4,Phase 3,Phase 2 85650-56-2, 65576-45-6 3001386
48
Molindone Approved Phase 4 7416-34-4 23897
49
Cycloserine Approved Phase 4,Phase 2,Phase 3 68-41-7 6234 401
50
Losartan Approved Phase 4 114798-26-4 3961

Interventional clinical trials:

(show top 50) (show all 644)

# Name Status NCT ID Phase Drugs
1 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
2 A Pharmacokinetic Study of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
3 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
4 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Unknown status NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
5 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
6 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
7 Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Unknown status NCT02307396 Phase 4 Olanzapine;Amisulpride;Risperidone;Haloperidol;Quetiapine;Perphenazine;Sulpiride;bromperidol;Zuclopenthixol;Thioridazine;Paliperidone;Ziprasidone;Benperidol;Fluspirilene;Pimozide;Perazine;Fluphenazine;Flupentixole;Sertindole
8 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
9 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
10 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
11 Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder Completed NCT00100776 Phase 4 Olanzapine
12 A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00253110 Phase 4 risperidone;haloperidol
13 An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment Completed NCT00526877 Phase 4 Risperidone
14 Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder Completed NCT00683709 Phase 4
15 Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder Completed NCT00501618 Phase 4 Fazaclo
16 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed NCT01855074 Phase 4 Risperidone
17 A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs Completed NCT00649064 Phase 4 Ziprasidone
18 A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder Completed NCT00650429 Phase 4 Ziprasidone
19 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
20 Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00090012 Phase 4 Olanzapine;Quetiapine
21 Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00373672 Phase 4 armodafinil (Nuvigil);placebo
22 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)? Completed NCT00306475 Phase 4 divalproex sodium ER;placebo
23 Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder Completed NCT00061802 Phase 4 risperidone, quetiapine
24 A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia Completed NCT00222794 Phase 4 Atomoxetine (Strattera)
25 Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone Completed NCT00406315 Phase 4 ziprasidone
26 Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin Completed NCT00177580 Phase 4 Pravastatin
27 Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00190749 Phase 4 olanzapine;risperidone
28 Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder. Completed NCT00325689 Phase 4 Quetiapine or Risperidone + Aripiprazole;Quetiapine or Risperidone + placebo
29 A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients Completed NCT00634348 Phase 4 Aripiprazole;Ziprasidone
30 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
31 A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine. Completed NCT00378183 Phase 4 risperidone
32 Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder Completed NCT00423878 Phase 4 Risperidone;Olanzapine;Quetiapine;Aripiprazole
33 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
34 Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease Completed NCT00535145 Phase 4 Treatment as usual (TAU), Paliperidone ER
35 Galantamine for Cognition in People With Schizophrenia Completed NCT00320736 Phase 4 galantamine
36 Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia Completed NCT02137993 Phase 4 A-prexa;Zyprexa
37 Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS) Completed NCT00304655 Phase 4 Aripiprazole
38 Effectiveness of Ziprasidone for Patients With Schizophrenia Completed NCT01198353 Phase 4 Ziprasidone
39 Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
40 A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT00236379 Phase 4 Olanzapine;Risperidone
41 Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia Completed NCT00320723 Phase 4 bupropion, transdermal nicotine patch
42 Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults Completed NCT00845507 Phase 4 Exenatide
43 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
44 An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia Completed NCT01309373 Phase 4
45 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
46 Lurasidone Effects on Tissue Glutamate in Schizophrenia Completed NCT02199743 Phase 4 Lurasidone;Haloperidol;Perphenazine
47 Effect of Single Dose Intranasal Insulin On Cognitive Function Completed NCT00646581 Phase 4 Placebo;Insulin (Humulin)
48 The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study) Completed NCT00816907 Phase 4 Metformin;Placebo
49 A Comparison of Long-acting Injectable Medications for Schizophrenia Completed NCT01136772 Phase 4 haloperidol decanoate;paliperidone palmitate
50 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4 ziprasidone

Search NIH Clinical Center for Schizoaffective Disorder

Genetic Tests for Schizoaffective Disorder

Anatomical Context for Schizoaffective Disorder

MalaCards organs/tissues related to Schizoaffective Disorder:

38
Brain, Testes, Heart, Liver, Tongue, Cerebellum, Cortex

Publications for Schizoaffective Disorder

Articles related to Schizoaffective Disorder:

(show top 50) (show all 572)
# Title Authors Year
1
Test-retest reliability of the diagnosis of schizoaffective disorder in childhood and adolescence - A systematic review and meta-analysis. ( 29360577 )
2018
2
Case series of diagnostic shift from bipolar disorder to schizoaffective disorder. ( 29189086 )
2018
3
Organization's Effects With Schizoaffective Disorder. ( 29325177 )
2018
4
The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. ( 29125018 )
2018
5
Learning to Live With Schizoaffective Disorder: A Transformative Journey Toward Recovery. ( 29346672 )
2018
6
Life events in schizoaffective disorder: A systematic review. ( 29172048 )
2018
7
Psychological Distress Among Caregivers of Individuals With a Diagnosis of Schizophrenia or Schizoaffective Disorder. ( 28967321 )
2018
8
Impact of irritability: a 2-year observational study of outpatients with bipolar I or schizoaffective disorder. ( 28470892 )
2017
9
Self versus informant reports on the specific levels of functioning scale: Relationships to depression and cognition in schizophrenia and schizoaffective disorder. ( 28740827 )
2017
10
Schizoaffective disorder, catatonia and white matter changes - Revisiting the microglial hypothesis. ( 28349728 )
2017
11
A rare presentation of auto-emasculation in a patient with schizoaffective disorder: Management with clozapine. ( 28777030 )
2017
12
Prevalence, characteristics and management of headache experienced by people with schizophrenia and schizoaffective disorder: a cross sectional cohort study. ( 28747114 )
2017
13
Moral cognition and homicide amongst forensic patients with schizophrenia and schizoaffective disorder: A cross-sectional cohort study. ( 28716450 )
2017
14
Heads Up: The Presentation of Schizoaffective Disorder in an Elite College Soccer Player with Prior Concussion. ( 29117025 )
2017
15
Characteristics and Service Use of Older Adults with Schizoaffective Disorder Versus Older Adults with Schizophrenia and Bipolar Disorder. ( 28478998 )
2017
16
Measuring the Work Impact of Caregiving for Individuals With Schizophrenia and/or Schizoaffective Disorder With the Caregiver Work Limitations Questionnaire (WLQ). ( 28777200 )
2017
17
Schizophrenia and induced abortions: A national register-based follow-up study among Finnish women born between 1965-1980 with schizophrenia or schizoaffective disorder. ( 28615119 )
2017
18
Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. ( 28923068 )
2017
19
Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial. ( 28541645 )
2017
20
The Effects of Psychoeducation on Long-term Inpatients with Schizophrenia and Schizoaffective Disorder. ( 28381728 )
2017
21
Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. ( 28454922 )
2017
22
Risk of gastrointestinal Hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: A retrospective cohort study. ( 29107449 )
2017
23
Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. ( 28470106 )
2017
24
Editorial Comment: Schizoaffective Disorder in Later Life: "Beware the Jabberwock". ( 28554538 )
2017
25
Blood serum concentrations of kynurenic acid in patients diagnosed with recurrent depressive disorder, depression in bipolar disorder, and schizoaffective disorder treated with electroconvulsive therapy. ( 28866716 )
2017
26
Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder. ( 28675307 )
2017
27
A neuropsychiatric case report: KlA1ver-Bucy and Gastaut-Geschwind syndromes in one patient with schizoaffective disorder presenting with brain 99-mTc HMPAO single-photon emission computed tomography showing bilateral discrete decrease of temporal lobes perfusion. ( 29061200 )
2017
28
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. ( 28839342 )
2017
29
Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. ( 29164928 )
2017
30
Genome-wide significant locus for Research Diagnostic Criteria Schizoaffective Disorder Bipolar type. ( 28851079 )
2017
31
Remission of Schizoaffective Disorder Using Homeopathic Medicine: 2 Case Reports. ( 28987077 )
2017
32
Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder. ( 27391238 )
2016
33
Admission-Based Prevalence of Schizophrenia, Schizoaffective Disorder and Bipolar I Disorder in a Catchment Area in Sinop, Turkey. ( 27711935 )
2016
34
The association between serum creatine kinase, mood and psychosis in inpatients with schizophrenia, bipolar and schizoaffective disorders. ( 27086253 )
2016
35
Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder. ( 28086013 )
2016
36
Emotional awareness and delusions in schizophrenia and schizoaffective disorder. ( 25434845 )
2015
37
Assessing the contribution of borderline personality disorder and features to suicide risk in psychiatric inpatients with bipolar disorder, major depression and schizoaffective disorder. ( 25661531 )
2015
38
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. ( 25562685 )
2015
39
Antipsychotic switching in schizoaffective disorder: A systematic review. ( 25751661 )
2015
40
Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. ( 25800457 )
2015
41
Paranoid Schizophrenia versus Schizoaffective Disorder: Neuropsychological Aspects. ( 26506747 )
2015
42
Patients with schizophrenia or schizoaffective disorder who receive multiple electroconvulsive therapy sessions: characteristics, indications, and results. ( 25848283 )
2015
43
A dimensional comparison between delusional disorder, schizophrenia and schizoaffective disorder. ( 26585220 )
2015
44
Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder. ( 25560755 )
2015
45
EEG correlates of a mental arithmetic task in patients with first episode schizophrenia and schizoaffective disorder. ( 25754261 )
2015
46
DSM-5 schizoaffective disorder: will clinical utility be enhanced? ( 25597039 )
2015
47
A comparison of schizophrenia, schizoaffective disorder, and bipolar disorder: Results from the Second Australian national psychosis survey. ( 25451392 )
2014
48
Serotonin-norepinephrine reuptake inhibitor-associated mixed episode in an adolescent with schizoaffective disorder. ( 24875069 )
2014
49
Trait or state? A longitudinal neuropsychological evaluation and fMRI study in schizoaffective disorder. ( 25242360 )
2014
50
Turner Mosaicism and Schizoaffective Disorder. ( 24951716 )
2014

Variations for Schizoaffective Disorder

Expression for Schizoaffective Disorder

Search GEO for disease gene expression data for Schizoaffective Disorder.

Pathways for Schizoaffective Disorder

GO Terms for Schizoaffective Disorder

Cellular components related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.62 COMT DRD2 GABRB1 HTR2A
2 axon GO:0030424 9.46 COMT DRD2 DTNBP1 HTR2A
3 dendritic spine GO:0043197 9.43 COMT DRD2 DTNBP1
4 postsynaptic membrane GO:0045211 9.26 COMT DISC1 DTNBP1 GABRB1
5 integral component of plasma membrane GO:0005887 9.23 DRD2 DRD3 GABRB1 HTR2A NOTCH4 PCDH11X

Biological processes related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.83 COMT DRD2 DRD3 HTR2A SLC6A4
2 response to toxic substance GO:0009636 9.73 DRD2 GABRB1 SLC6A4
3 arachidonic acid secretion GO:0050482 9.61 DRD2 DRD3
4 temperature homeostasis GO:0001659 9.6 DRD2 HTR2A
5 dopamine receptor signaling pathway GO:0007212 9.59 DRD2 DRD3
6 positive regulation of neuroblast proliferation GO:0002052 9.58 DISC1 DRD2
7 synaptic transmission, dopaminergic GO:0001963 9.58 DRD2 DRD3
8 negative regulation of protein secretion GO:0050709 9.57 DRD2 DRD3
9 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.55 DRD2 HTR2A
10 prepulse inhibition GO:0060134 9.54 DRD2 DRD3
11 positive regulation of renal sodium excretion GO:0035815 9.52 DRD2 DRD3
12 G-protein coupled receptor internalization GO:0002031 9.51 DRD2 DRD3
13 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.49 DRD2 DRD3
14 regulation of cAMP metabolic process GO:0030814 9.48 DRD2 DRD3
15 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.46 DRD2 DRD3
16 negative regulation of dopamine receptor signaling pathway GO:0060160 9.4 DRD2 DRD3
17 acid secretion GO:0046717 9.37 DRD2 DRD3
18 behavioral response to cocaine GO:0048148 9.33 DRD2 DRD3 HTR2A
19 response to histamine GO:0034776 9.32 DRD2 DRD3
20 regulation of locomotion involved in locomotory behavior GO:0090325 9.26 DRD2 DRD3
21 dopamine metabolic process GO:0042417 9.13 COMT DRD2 DRD3
22 regulation of dopamine secretion GO:0014059 8.92 DRD2 DRD3 DTNBP1 HTR2A

Molecular functions related to Schizoaffective Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.33 DRD2 DRD3 HTR2A
2 dopamine binding GO:0035240 9.26 DRD2 DRD3
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.96 DRD2 DRD3
4 dopamine neurotransmitter receptor activity GO:0004952 8.62 DRD2 DRD3

Sources for Schizoaffective Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....